<SEC-DOCUMENT>0001213900-22-030955.txt : 20220602
<SEC-HEADER>0001213900-22-030955.hdr.sgml : 20220602
<ACCEPTANCE-DATETIME>20220602163006
ACCESSION NUMBER:		0001213900-22-030955
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220602
FILED AS OF DATE:		20220602
DATE AS OF CHANGE:		20220602

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SciSparc Ltd.
		CENTRAL INDEX KEY:			0001611746
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38041
		FILM NUMBER:		22991221

	BUSINESS ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916
		BUSINESS PHONE:		972-3-6103100

	MAIL ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SciSparc Ltd./ADR
		DATE OF NAME CHANGE:	20210129

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Therapix Biosciences Ltd.
		DATE OF NAME CHANGE:	20140624
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea161055-6k_scisparc.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Report of Foreign Private Issuer<BR>
Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the month of June 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Report No. 2)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission file number: 001-38041</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>SCISPARC LTD.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>20 Raul Wallenberg Street, Tower A,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Tel Aviv 6971916 Israel</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>
Form 40-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): <U>&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): <U>&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 2, 2022, SciSparc Ltd.
(the &ldquo;Company&rdquo;) issued a press release titled &ldquo;SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields Another
Patent Application for their Proprietary Psychedelic Combination to Treat Cocaine Addiction&rdquo;. A copy of this press release is furnished
herewith as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The first and second
paragraphs and the section titled &ldquo;Forward-Looking Statements&rdquo; in the press release attached as Exhibit 99.1 are
incorporated by reference&nbsp;into the registration statements on Form F-3 (File No. <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390019016523/ff32019_therapixbio.htm">333-233417</A>
and File No. <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390020025655/ea126468-f1_therapixbio.htm">333-248670</A>)
and on Form S-8 (File No. <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390018008005/fs82018_therapixbiosciences.htm">333-225773</A>)
of the Company, filed with the SEC, to be a part thereof from the date on which this report is submitted, to the extent not
superseded by documents or reports subsequently filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT INDEX</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 90%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="ea161055ex99-1_scisparc.htm">Press Release issued by SciSparc Ltd. on June 2, 2022 titled &ldquo;SciSparc
Ltd. and Clearmind Medicine Inc. Collaboration Yields Another Patent Application for their Proprietary Psychedelic Combination to Treat
Cocaine Addiction&rdquo;.</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt"><B>SciSparc Ltd.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: June 2, 2022</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Oz Adler </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="width: 31%"><FONT STYLE="font-size: 10pt">Oz Adler</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer &amp; <BR>
Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea161055ex99-1_scisparc.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY SCISPARC LTD. ON JUNE 2, 2022 TITLED "SCISPARC LTD. AND CLEARMIND MEDICINE INC. COLLABORATION YIELDS ANOTHER PATENT APPLICATION FOR THEIR PROPRIETARY PSYCHEDELIC COMBINATION TO TREAT COCAINE ADDICTION"
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SciSparc Ltd. and Clearmind Medicine Inc. Collaboration
Yields Another  Patent Application for their Proprietary Psychedelic Combination to Treat Cocaine Addiction</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>No dedicated treatment currently available for
cocaine addiction </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TEL AVIV, Israel, June 02, 2022 (GLOBE NEWSWIRE) --
 SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders
of the central nervous system (the &quot;Company&quot; or &quot;SciSparc&quot;), today announced that its recently launched collaboration
with Clearmind Medicine Inc. (&ldquo;Clearmind&rdquo;) (CSE: CMND), (OTC: CMNDF), (FSE:&nbsp;CWY0), a biotech company focused on discovery
and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, resulted in the filing of a provisional
patent application related to treating cocaine addiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The patent application refers to the proprietary
combination of SciSparc's CannAmide&trade; with Clearmind's MEAI, for treating cocaine addiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States cocaine addiction peaked in
the 1990s, and the current estimates by the National Institute on Drug Abuse claim at least 1.3 million Americans are addicted to cocaine.
Annually, these users go to the hospital more than 350,000 times and account for 54% of drug-related incarcerations in federal jails and
prisons, according to recent statistics from the U. S. Department of Justice. In addition, cocaine is either suspected or confirmed as
the cause for nearly 16,000 overdose deaths each year in the United States. Furthermore, it is at least a contributing factor in many
more deaths, usually from violence, associated medical conditions or other health impacts of the user&rsquo;s lifestyle.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&quot;The continuous successes of our relatively
new collaboration with Clearmind strengthen our belief that combining our CannAmide&trade; with Clearmind's novel psychedelic molecule,
MEAI, holds great potential for treating various addictions and dependency conditions,&rdquo; commented Oz Adler, SciSparc's Chief Executive
Officer. &ldquo;Cocaine abuse in the United States is a serious and growing issue that affects all ages. Despitethe highly addictive nature
of cocaine, a dedicated treatment for this addiction does not currently exist,which makes the potential for our treatment even more exciting.
In light of the encouraging results generated from this collaboration and following our first patent application for binge behavior announced
in May, we intend to continue to strengthen and expand our collaboration with Clearmind.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About SciSparc (NASDAQ:SPRC):</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SciSparc Ltd. is a specialty clinical-stage pharmaceutical
company led by an experienced team of senior executives and scientists. SciSparc&rsquo;s focus is on creating and enhancing a portfolio
of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug
development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette syndrome and for the
treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder
and status epilepticus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>About Clearmind (CSE: CMND), (OTC: CMNDF), (FSE:&nbsp;CWY0)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clearmind is a psychedelic pharmaceutical biotech
company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health
problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to
commercialize them as regulated medicines, foods or supplements. Clearmind&rsquo;s intellectual portfolio currently consists of four patent
families. Clearmind intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the
acquisition of additional intellectual property to build its portfolio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Forward-Looking Statements:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains forward-looking statements
within the meaning of the &quot;safe harbor&quot; provisions of the Private Securities Litigation Reform Act of 1995 and other Federal
securities laws. For example, SciSparc is using forward-looking statements when it discusses the potential benefits of CannAmide&trade;
combined with MEAI for treating cocaine abuse and the intention of SciSparc to expand its collaboration with Clearmind. Historic results
of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest
identical or even similar conclusions. Because such statements deal with future events and are based on SciSparc's current expectations,
they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially
from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this
press release are subject to other risks and uncertainties, including those discussed under the heading &quot;Risk Factors&quot; in SciSparc's
Annual Report on Form 20-F filed with the SEC on&nbsp;April [28], 2022, and in subsequent filings with the U.S. Securities and Exchange
Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking
statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or
otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Investor Contact:<BR>
</B><U>IR@scisparc.com</U><BR>
Tel: +972-3-6167055</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "0 ) # 2(  A$! Q$!_\0
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M5--U=OE4%OW4Y_V2>A_V3^!->J4 %%%% !1110 4444 %%%% !1110 4444
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L71:+8W6FZ3!:7NHS:C<Q@^9=3*JM(22>@X YP!Z 5?HH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
